Joshua P. Taygerly

AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies

Sean Caenepeel, Sean P. Brown, Brian Belmontes et al. · Cancer Discovery · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +14

Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction

K.R. Simonetta, Joshua P. Taygerly, Kathleen Boyle et al. · Nature Communications · 2019 · 209 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis

Yan Lou, Xiaochun Han, A. Kuglstatter et al. · Journal of Medicinal Chemistry · 2014 · 108 citations

Pharmacy, Medicinal Chemistry, Pharmacology +16

A convenient guide to help select replacement solvents for dichloromethane in chromatography

Joshua P. Taygerly, Larry Miller, Alicia Yee et al. · Green Chemistry · 2012 · 89 citations

Natural Sciences, Chemistry, Medicinal Chemistry +17

Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells

Gabriele Picco, Yanhua Rao, Angham Al Saedi et al. · Cancer Discovery · 2024 · 51 citations · Full text

Life Sciences, Molecular Biology, Oncology +17